Peter Lynch · Growth at a reasonable price (GARP)
Is Xeris Biopharma Holdings, Inc. (XERS) a Peter Lynch Stock?
Strong GARP candidate: growth at a reasonable price.
84/100
Mixto
3/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a XERS
PEG ≤ 1.0
clave-
EPS CAGR ≥ 15%
clave-
Revenue CAGR ≥ 10%
55.8%
Net margin > 0
3.8%
Cómo se valora XERS en otras estrategias
Datos financieros en vivo
Cap. mercado
$1.85B
PER (TTM)
92.7x
ROIC (TTM)
12.84%
Margen bruto
81.59%
Otros análisis Peter Lynch
Preguntas frecuentes
What is XERS's Peter Lynch fit score?
XERS scores 84/100 on our Peter Lynch fit engine. Strong GARP candidate: growth at a reasonable price.
Does Peter Lynch actually own XERS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends XERS.
How often is this score updated?
XERS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende XERS personalmente.
